| Nancy Lm Wilcox, FNP | |
|
1500 Portland Ave, Rochester, NY 14621-3065 | |
| (585) 697-6416 | |
| Not Available |
| Full Name | Nancy Lm Wilcox |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 8 Years |
| Location | 1500 Portland Ave, Rochester, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003356668 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | F341535-1 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rochester General Hospital | Rochester, NY | Hospital |
| Finger Lake Health-geneva General Hospital | Geneva, NY | Hospital |
| Newark-wayne Community Hospital | Newark, NY | Hospital |
| Clifton Springs Hospital And Clinic | Clifton springs, NY | Hospital |
| Soldiers And Sailors Memorial Hospital Of Yates | Penn yan, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Western New York Medical Practice Pc | 3870767791 | 423 |
News Archive
Many cancer patients do not get the opportunity to discuss their wishes for treatment until their illness has progressed too far, when it may be too late to have those discussions with loved ones or physicians.
Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.
A mouse resistant to cancer, even highly-aggressive types, has been created by researchers at the University of Kentucky.
Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care, medical research and training of outstanding young health professionals.
Gilead Sciences, Inc. has announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg). Atripla is currently sold in the United States through a joint venture between Bristol-Myers Squibb and Gilead.
› Verified 7 days ago
| Entity Name | Rochester General Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356412712 PECOS PAC ID: 0244149474 Enrollment ID: O20031121000644 |
News Archive
Many cancer patients do not get the opportunity to discuss their wishes for treatment until their illness has progressed too far, when it may be too late to have those discussions with loved ones or physicians.
Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.
A mouse resistant to cancer, even highly-aggressive types, has been created by researchers at the University of Kentucky.
Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care, medical research and training of outstanding young health professionals.
Gilead Sciences, Inc. has announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg). Atripla is currently sold in the United States through a joint venture between Bristol-Myers Squibb and Gilead.
› Verified 7 days ago
| Entity Name | St Anns Home For The Aged |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225067168 PECOS PAC ID: 5092758938 Enrollment ID: O20050602000333 |
News Archive
Many cancer patients do not get the opportunity to discuss their wishes for treatment until their illness has progressed too far, when it may be too late to have those discussions with loved ones or physicians.
Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.
A mouse resistant to cancer, even highly-aggressive types, has been created by researchers at the University of Kentucky.
Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care, medical research and training of outstanding young health professionals.
Gilead Sciences, Inc. has announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg). Atripla is currently sold in the United States through a joint venture between Bristol-Myers Squibb and Gilead.
› Verified 7 days ago
| Entity Name | Western New York Medical Practice Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063790608 PECOS PAC ID: 3870767791 Enrollment ID: O20111110000598 |
News Archive
Many cancer patients do not get the opportunity to discuss their wishes for treatment until their illness has progressed too far, when it may be too late to have those discussions with loved ones or physicians.
Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.
A mouse resistant to cancer, even highly-aggressive types, has been created by researchers at the University of Kentucky.
Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care, medical research and training of outstanding young health professionals.
Gilead Sciences, Inc. has announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg). Atripla is currently sold in the United States through a joint venture between Bristol-Myers Squibb and Gilead.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nancy Lm Wilcox, FNP 1500 Portland Ave, Rochester, NY 14621-3065 Ph: (585) 697-6416 | Nancy Lm Wilcox, FNP 1500 Portland Ave, Rochester, NY 14621-3065 Ph: (585) 697-6416 |
News Archive
Many cancer patients do not get the opportunity to discuss their wishes for treatment until their illness has progressed too far, when it may be too late to have those discussions with loved ones or physicians.
Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.
A mouse resistant to cancer, even highly-aggressive types, has been created by researchers at the University of Kentucky.
Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care, medical research and training of outstanding young health professionals.
Gilead Sciences, Inc. has announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg). Atripla is currently sold in the United States through a joint venture between Bristol-Myers Squibb and Gilead.
› Verified 7 days ago
Sarah Anne Rossi, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 601 Elmwood Ave, Box 652, Rochester, NY 14642 Phone: 585-279-5100 | |
Mrs. Anne Scherberger Keefer, RN NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 601 Elmwood Ave, Box 704, Rochester, NY 14642 Phone: 585-275-5307 Fax: 585-275-2914 | |
Sarah Siegfried, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 601 Elmwood Ave, Box 619-334, Rochester, NY 14642 Phone: 585-472-5690 | |
Mr. Seth Christopher Jacob-wagner, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 114 University Ave, Rochester, NY 14605 Phone: 585-546-2271 | |
Ashley Lynn Hendershot, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 125 Red Creek Dr, Rochester, NY 14623 Phone: 585-486-0600 | |
Caitlin Patrice Curtin, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 601 Elmwood Ave, Rochester, NY 14642 Phone: 585-275-2100 |